Business Context and Reporting Period
This Form 8-K is a current report filed by Point Capital, Inc. on November 27, 2015. The filing addresses a significant change in corporate governance and management. Note: The request metadata references "Silo Pharma, Inc.," but the filing text explicitly identifies the registrant as Point Capital, Inc.
Key Financial Metrics
The filing text does not provide any financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report is strictly limited to a personnel change.
Material Changes
- Departure of Leadership: Richard Brand resigned effective November 27, 2015, from his positions as Chairman, Chief Executive Officer, and member of the Board of Directors.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Interim Appointment: Eric Weisblum, currently the President, has assumed the roles of Chairman and Chief Executive Officer pending the appointment of a successor.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business performance. The primary contingency noted is the potential for future disclosure: if subsequent communications with Mr. Brand reveal any disagreement with the Company, the Board, or executive officers, the Company will amend this report to disclose such disagreement.
Investor Verification Checklist
- Verify the identity of the registrant (Point Capital, Inc.) versus the metadata request (Silo Pharma, Inc.).
- Confirm the effective date of Richard Brand's resignation (November 27, 2015).
- Monitor for the appointment of a permanent successor to the Chairman and CEO roles.
- Watch for any amended filings that might disclose a disagreement regarding the resignation.